Immunology

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

Over the past 10 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year, we assemble an international mix of thought leaders and decision makers from industry and academia to bring you the latest developments in immuno-oncology, while providing access to a comprehensive 3-day program and extensive networking opportunities that CHI’s IO Summit provides.

We’ll examine challenges facing the industry with NEW case studies, NEW perspectives and NEW approaches. Learn from industry, academia and the FDA at 3 Conference Programs, Symposium, Training Seminar, Workshop and 5 Short Courses. Once again, we’ll host interactive breakouts on various niche topics so delegates can share experiences and generate new ideas. 

Engage in scientific discussions on the latest tools and technologies for accelerated NK-based cellular immunotherapy development. Benefit from exclusive insights from global influencers in NK based cell therapy, addressing strategies for safety, quality control and off-target activity assessment, with the goal to fast track to clinic.

A gatering of the entire conference community of life sciences, pharmaceutical, clinical, healthcare, and IT professionals at the leading edge of molecular engineering and therapeutic design.

The World Vaccine & Immunotherapy Congress West Coast is part of an award-winning series of conferences and exhibitions that are continuously growing becoming the largest and most established vaccine meetings of its kind across the globe. Scientific Affairs • Immunotherapy • Influenza • Infectious Disease • R&D • Regulatory Affairs • Manufacturing • Immunology • Oncology • Vaccines • Clinical Development • Partnerships

Uncover how companies are furthering their understanding of the tumour microenvironment through the latest technologies, including spatial imaging and novel biomarkers. Gain insights in emerging therapeutic opportunities through targeting the tumour microenvironment with immunooncology.

The latest science and research on antibody engineering, design and selection diving into critical topics including immuno-oncology, cellular engagers, miniproteins, the Fc region, cancer therapy, novel bi-specifics/multispecifics and much more!

Immuno-Oncology (IO) 360° takes a strategic look at the business and scientific aspects of Immuno-Oncology.  With significant in-put from Lead Advisors Dr. Axel Hoos (former CEO of Scorpion Therapeutics) and Dr. James Gulley (NCI,) the conference examines the current landscape, and reports on the latest advancements in IO to improve and accelerate clinical trials. The audience is comprised of roughly 500 top executives at Pharma companies and Biotechs, as well as the financial community, consultants and leading research organizations in the field of Immuno-Oncology.  

As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy. The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally. With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:Optimize stable expansion of Tregs to maintain function to elicit durable responses
Decode Treg interactions to optimize the mechanism of actions and inform biomarker development
Rationalize activation, formulation & delivery strategy to induce antigen specific tolerance
Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy